Salute e Benessere

Global CAR-T Cell Therapy Market to Hit $217.6Bn by 2035 at 39.75% CAGR |…

"While much of the industry's focus has historically been on CAR-T in blood cancers, our study expands the lens to solid tumors and tracks over 1,000 global clinical trials, providing critical intelligence for biopharma strategy teams navigating this rapidly evolving landscape," said Nneha Rathod Godbole, Founder and CEO at Vantage Market Research. "CAR-T therapy is revolutionizing oncology care by transitioning from a last-resort option to a mainstream precision therapy with…

Large Independent Randomized Controlled Trial Validates MolecuLight's…

"This randomized trial demonstrates that MolecuLight delivers measurable, clinically significant benefits in wound management," said Dr. Shun-Cheng Chang, senior author and Associate Professor, Department of Surgery, Integrated Burn & Wound Care Center, Shuang-Ho Hospital. "The ability to visualize bacterial burden in real time allows surgeons to achieve higher-quality debridement and faster healing, while also serving as an invaluable teaching tool for training younger…

Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Key Improvements: Key Improvements: Begin Your Exploration TodayOpenDEL™ 5.0 is now available worldwide. Let HitGen help you with your next drug discovery breakthrough. Visitwww.hitgen.com or contact our team to learn more. Logo -https://mma.prnewswire.com/media/2758868/HitGen_Logo_Logo.jpg View original content: https://www.prnewswire.co.uk/news-releases/advancing-del-technology-for-the-research-lab-hitgen-introduces-opendel-5-0--302539766.html

clock.bio Appoints Former BioNTech Executive Dr. Michael Boehler as Chief…

"Michael played a central role in one of the most significant product launches in pharmaceutical history," said Markus Gstöttner, CEO of clock.bio. "His experience in BioNTech's global commercial scale-up, combined with his proven ability to build partnerships, makes him uniquely suited to help clock.bio translate breakthrough science into therapies that extend healthspan." "Michael played a central role in one of the most significant product launches in pharmaceutical…

Resolution Therapeutics to host virtual R&D webinar alongside world leading…

The R&D webinar will be moderated by Amir Hefni, Ph.D., Chief Executive Officer at Resolution, and include presentations from Resolution's Chief Medical Officer Cliff Brass, M.D., Ph.D. and SVP, Head of Research and Translational Science Lara Campana. Chief Investigator of the Phase 1/2 EMERALD study, Professor Jonathan Fallowfield, Chair of Translational Liver Research and Principal Investigator at the University of Edinburgh, Honorary Consultant Hepatologist at the Royal Infirmary of…

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with…

The differentiated R&D pipeline advanced significantly. Key highlights include: The differentiated R&D pipeline advanced significantly. Key highlights include: Global academic influence was underscored by publications in top-tier journals like The New England Journal of Medicine (for CM336 in autoimmune hemolytic anemia), Nature Medicine, and JAMA for Stapokibart's pivotal studies. Stapokibart was also included in Chinese treatment guidelines. With robust cash reserves,...

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Aug.27, 2025(GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,...

KONE Egypt and United Elevators Sign Strategic Contract to Expand Market Reach…

Ahmed Fathi, Managing Director of KONE Egypt, said:"This partnership is a strong step forward in our ambition to reach more customers and better serve the evolving needs of the Egyptian market. As our first Channel Partner in the country, United Elevators brings a strong local track record that will allow us to scale more efficiently and bring KONE's world-class solutions even closer to the people and businesses who need them, whether it's a landmark development, a residential building, or…

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and…

Radspherin® Radspherin® Corporate CEO Øystein Soug and CFOTore Kvamwill present the results for the first half of 2025 at a webcast available athttps://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27 August at08:00 CEST. The presentation and Q&A will be held in English. A recording of the webcast will be made available on our website shortly after the presentation. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company...

XRP Healthcare M&A Holding Inc. Launches Africa's First HIPAA-Grade Digital…

"Africa deserves the same privacy standards as New York or London," said Kain Roomes, Founder and CEO of XRP Healthcare. "By making XRPH AI HIPAA-grade and keeping all patient data on the device, we've set a gold standard that puts control where it belongs—with the individual." " Africadeserves the same privacy standards asNew YorkorLondon," saidKain Roomes, Founder and CEO of XRP Healthcare. "By making XRPH AI HIPAA-grade and keeping all patient data on the…

Idorsia successfully completes convertible bonds restructuring

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 ( CB 2025 ; ISIN CH0426820350) and CHF 600 million convertible bonds maturing in 2028 ( CB 2028 ; ISIN CH1128004079) launched on June 25, 2025 (theRepurchase Offer ).Bondholders accepted the Repurchase Offer for the CB 2025 with an aggregate nominal value of CHF 187,476,000,...

Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational…

Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025Halle (Saale) / Munich, Germany, August 27 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its half year financial results for the period ended June 30, 2025 and...

Junshi Biosciences Announces 2025 Interim Financial Results and Provides…

FINANCIAL HIGHLIGHTSAs of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI ®(toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024.Total research and development (“R&D”) expenses of the company were...

CAR-T Cell Therapy Market to Reach USD 11,142.53 million by 2032, growing at a…

According to Credence Research, the CAR-T Cell Therapy Market is set to witness robust growth, advancing from USD 4,405 million in 2024 to USD 11,142.53 million by 2032. This expansion represents a strong CAGR of 12.3% during the forecast period. The rapid rise reflects growing adoption of personalized cancer treatments, continuous clinical advancements, and increasing approvals of innovative CAR-T therapies worldwide. According to Credence Research, theCAR-T Cell Therapy Marketis set to...

Consumer Packaged Goods (CPG) Market to Reach USD 2.59 Trillion by 2031 | Driven…

Get Free Sample on CPG Market Report Get Free Sample on CPG Market Report What are the key factors driving the growth of the Consumer packaged goods market? Theconsumer packaged goods (CPG) marketremains a vital and resilient sector due to the essential nature of its offerings. Shifts inlifestyle, values, and technologyare reshaping consumer demand. Companies are adapting through: Growth is fueled by the interplay between: The competitive landscape is dynamic,...

Cosmetic Surgery Market Size worth US$ 73.09 billion by 2033 with 7.9% CAGR…

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cosmetic-surgery-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cosmetic-surgery-market Surge in Non-Surgical Treatments Minimally invasive procedures, such as botulinum toxin injections, dermal fillers, and chemical peels, are at the forefront of the...

Healthcare IT Market is Expected to Reach USD 1033.78 Billion by 2032 | SkyQuest…

Get a Free Sample Report: https://www.skyquestt.com/sample-request/healthcare-it-market Get a Free Sample Report:https://www.skyquestt.com/sample-request/healthcare-it-market Healthcare IT Market Key Growth Drivers Surge in prevalence of chronic diseases and growing geriatric population have resulted in increased burden on healthcare infrastructure. Healthcare institutions are focusing on opting for advanced technologies to manage the rising patient load and improve remote care and...

Surgical Microscopes Market worth US$2.69 billion by 2030 with 11.4% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179225920 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179225920 Browse in-depth TOC on "Surgical Microscopes Market" 188 - Tables 58 - Figures 227 - Pages By product type,the surgical microscopes market comprises three product segments: devices, accessories, and software. The devices segment is experiencing strong growth due to the demand for...

PCI Biotech: Invitation to first half 2025 results presentation and corporate…

The presentation will be held in Norwegian as a live webcast available through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. Please submit questions [email protected] to the webcast. It will be possible to post written questions through the webcast console during the session.The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day...

Neurology Devices Market Size to Reach US$ 43.28 Billion by 2033 - Exclusive…

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response) - https://www.datamintelligence.com/download-sample/neurology-devices-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response) - https://www.datamintelligence.com/download-sample/neurology-devices-market AI-Powered Brain Stimulation Enhances Treatment Precision Technological advancements are revolutionizing the neurology devices market, particularly in brain...

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual…

Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq:GMAB)announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conferencein New York City, NYat 7:45AMEDT (1:45 PM CEST)on September 9 , 2025 . A webcast of the fireside chat will be available on...

Beko Becomes Official Confidence Partner of Ajax

As Official Confidence Partner, Beko will supportAjax'smission to develop the next generation of football talent, both on and off the pitch, while reinforcing "A Beko state of mind," offering reliable and quality home appliances with advanced solutions that give consumers the confidence they've made the right choice. Beko's partnership withAjaxalso reflects its deepening commitment to theAmsterdamandThe Netherlandsregion, and to communities who share its belief in...

Hydrachem brings next-gen disinfection and hygiene solutions to WHX Cape Town

Leading the portfolio is Biospot™, a professional-grade disinfectant that eliminates harmful microorganisms quickly without compromising on safety. Leading the portfolio isBiospot ™, a professional-grade disinfectant that eliminates harmful microorganisms quickly without compromising on safety. Alongside it,Cert ™ is also being showcased at WHX. Cert™ is Hydrachem's targeted disinfectant technology designed for spot-cleaning and high-contamination areas, now enhanced by Cert™ Bleach...

AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune…

About the MosaiQ solution The MosaiQ solution is a next-generation IVD solution for autoimmune diseases, allergies and beyond. The multiplexed, fully automated planar microarray platform enables syndromic testing for complex conditions. Designed with ease-of-use in mind, MosaiQ combines high throughput with continuous random access and delivers fast and accurate results addressing evolving expectations for laboratory efficiency. Key benefits include: Simple workflow...

Altri Comunicati